Intellia Therapeutics (NTLA) Scheduled to Post Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Intellia Therapeutics to post earnings of ($1.35) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The firm had revenue of ($1.92) million for the quarter, compared to analysts’ expectations of $15.10 million. During the same period in the prior year, the firm earned ($1.40) earnings per share. On average, analysts expect Intellia Therapeutics to post $-6 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Intellia Therapeutics Trading Up 0.7 %

NASDAQ:NTLA opened at $23.88 on Wednesday. The stock has a market capitalization of $2.30 billion, a P/E ratio of -4.41 and a beta of 1.85. Intellia Therapeutics has a 1 year low of $19.37 and a 1 year high of $47.48. The firm has a 50 day moving average of $25.84 and a 200-day moving average of $27.25.

Analysts Set New Price Targets

NTLA has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. The Goldman Sachs Group downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. Canaccord Genuity Group raised their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, Wedbush reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $67.00.

Insider Activity

In related news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the sale, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.00% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.